These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 33101285)

  • 41. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
    Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L
    J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
    Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
    J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
    Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 49. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
    Ren PP; Li M; Li TF; Han SY
    Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
    Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
    Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
    Qian S; Villarejo-Campos P; Guijo I; Hernández-Villafranca S; García-Olmo D; González-Soares S; Guadalajara H; Jiménez-Galanes S; Qian C
    Front Immunol; 2022; 13():841425. PubMed ID: 35401510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
    Shiina S; Ohno M; Ohka F; Kuramitsu S; Yamamichi A; Kato A; Motomura K; Tanahashi K; Yamamoto T; Watanabe R; Ito I; Senga T; Hamaguchi M; Wakabayashi T; Kaneko MK; Kato Y; Chandramohan V; Bigner DD; Natsume A
    Cancer Immunol Res; 2016 Mar; 4(3):259-68. PubMed ID: 26822025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
    Johnson LA; Scholler J; Ohkuri T; Kosaka A; Patel PR; McGettigan SE; Nace AK; Dentchev T; Thekkat P; Loew A; Boesteanu AC; Cogdill AP; Chen T; Fraietta JA; Kloss CC; Posey AD; Engels B; Singh R; Ezell T; Idamakanti N; Ramones MH; Li N; Zhou L; Plesa G; Seykora JT; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2015 Feb; 7(275):275ra22. PubMed ID: 25696001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Next-generation CAR T cell therapies for glioblastoma.
    Bernstock JD; Gerstl JVE; Valdés PA; Friedman GK; Chiocca E
    Sci Transl Med; 2024 Aug; 16(762):eadp2660. PubMed ID: 39196960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.